-
Sale!
14 critical success factors for medical device contract manufacturers including QMS and cybersecurity. -
Sale!
Analysis of pharmaceutical cGMP compliance risk and regulatory enforcement trends 2023-2025. -
Sale!
Comprehensive cGMP framework covering quality standards digital transformation and cybersecurity in 2025. -
Sale!
FDA regulatory trends and risk management strategies for clinical development of drugs and devices. -
Sale!
Strategic audit preparedness for combination products including QMSR implementation and cybersecurity. -
Sale!
Foundational and emerging principles driving pharmaceutical manufacturing excellence in the digital age. -
Sale!
Comprehensive guide to establishing 16 critical QMS elements aligned with FDA and ICH standards. -
Sale!
Comprehensive framework for ALCOA++ compliance and regulatory expectations in data integrity programs. -
Sale!
Strategic guide to change control as enabler of innovation aligned with FDA QMSR and ISO 13485:2016 requirements. -
Sale!
Strategic insights on design controls, cybersecurity, and QMSR transition for medical device manufacturers navigating AI-enabled technologies. -
Sale!
Comprehensive strategies for establishing robust GMP compliance programs including QMS, risk management, supplier quality, and advanced manufacturing approaches. -
Sale!
Comprehensive guide to quality risk management in biopharmaceutical manufacturing with latest ICH Q9(R1) guidance. -
Sale!
Strategic approach to medical device quality system improvements addressing QMSR harmonization and cybersecurity requirements. -
Sale!
Framework for establishing and implementing KPIs to drive quality management system continuous improvement and organizational excellence. -
Sale!
Essential framework for pharmaceutical manufacturing excellence through comprehensive microbiological contamination control strategies and best practices. -
Sale!
Quality by Design (QbD) is a paradigm shift that redefines quality assurance in pharmaceutical manufacturing by building quality into product and process design rather than relying solely on end-product testing. -
Sale!
A comprehensive guide to risk-based validation approaches for pharmaceutical and medical device manufacturing, providing strategies to prioritize validation efforts based on product risk. -
Sale!
Detailed strategies for equipment and software validation using risk-based approaches aligned with current FDA guidance and industry best practices. -
Sale!
Risk management strategies for combination products that merge drugs, devices, and/or biological products under 21 CFR Parts 211, 820, and 1271. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart D (Equipment) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart E (Control of Components and Drug Product Containers and Closures) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart F (Production and Process Controls) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive records and reports enforcement data 2017-2025 -
Sale!
Comprehensive packaging and labeling enforcement data 2017-2025 -
Comprehensive holding and distribution enforcement data 2017-2025 -
Sale!
Comprehensive laboratory controls enforcement data 2017-2025 -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart B – Quality System Requirements (§820.20 Management responsibility, §820.22 Quality audit, §820.25 Personnel). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart C – Design Controls (§820.30). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart D – Document Controls (§820.40). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart E – Purchasing Controls (§820.50). Form 483 observations and Warning Letters 2017–2025. -
FDA enforcement citation analysis for 21 CFR Part 820 Subpart F – Identification and Traceability (§820.60 Identification, §820.65 Traceability). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart G – Production and Process Controls (§820.70, §820.72 Inspection/measuring/test equipment, §820.75 Process validation). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart H – Acceptance Activities (§820.80 Receiving/in-process/finished device acceptance, §820.86 Acceptance status). Form 483 observations and Warning Letters 2017–2025.
ComplyFDA delivers authoritative compliance intelligence for pharmaceuticals, medical devices, biologics, and combination products, giving your team the clarity needed to strengthen inspection readiness, evaluate compliance risks, and support continuous quality improvement.
services.
get in touch.
© 2012 - 2026 • Avada is a Website Builder for WordPress and eCommerce • All Rights Reserved • Developed by ThemeFusion
